🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSemaglutide (Ozempic / Wegovy)Insurance denied me AGAIN - I am so frustrated — 12 month update

Insurance denied me AGAIN - I am so frustrated — 12 month update

NeuroNate Tue, Jan 9, 2024 at 10:43 AM 9 replies 2,226 viewsPage 1 of 2
This thread is more than 29 months old. Information may be outdated. Consider searching for more recent discussions.
NeuroNate
Senior Member
2,890
16,789
Dec 2023
Chicago, IL
Jan 9, 2024 at 10:43 AM#1

The list price and the price I actually pay differ by a factor of six depending on which of four routes I use, and none of that is transparent from the outside.

What I am trying to establish is what actually works on a prior-authorisation denial, as opposed to the list of things that sound like they should work.

Numbers rather than impressions, if you have them.

12 7jason_paloalto, Dr.LeslieOBGYN, MikeNYC_runner and 9 others
Reply Quote Save Share Report
anders_CPH
Senior Member
1,567
7,234
Feb 2024
Copenhagen, DK
Jan 9, 2024 at 11:39 AM#2
NeuroNate said:
The list price and the price I actually pay differ by a factor of six depending on which of four routes I use, and none of that is transparent from…
NeuroNate said:
...regarding the discontinuation data for cost and coverage...

I want to reframe the discontinuation narrative. We don't say "insulin fails because blood sugar rises when you stop it." We don't say "antihypertensives fail because BP goes up without them."

Why do we apply different logic to anti-obesity medications? The answer is stigma. We still, unconsciously, believe obesity is about willpower rather than biology. The discontinuation data actually PROVES it's a chronic biological condition requiring ongoing treatment.

This reframing isn't semantic — it has implications for insurance coverage, treatment duration, and patient expectations.

11 6MariaRD, AussieAnna, BethLabQueen and 8 others
Reply Quote Save Share Report
dan_philly
Member
456
2,123
Jul 2024
Philadelphia, PA
Jan 9, 2024 at 12:35 PM#3
anders_CPH said:
NeuroNate said: ...regarding the discontinuation data for cost and coverage...
anders_CPH said:
...my insurance denied cost and coverage coverage because...

Insurance denial is the single biggest barrier to GLP-1 access. Let me share the appeal framework that worked for me and several community members:

  1. Document medical necessity (BMI, comorbidities, failed alternatives)
  2. Reference clinical practice guidelines (AGA, AACE, Endocrine Society)
  3. Cite cost-effectiveness data (preventing diabetes/surgery saves money long-term)
  4. Request peer-to-peer review between your doctor and the plan's medical director
  5. File external appeal with your state insurance department if internal appeal fails

Don't accept the first denial. The appeal process exists for a reason.

Last edited: Jan 9, 2024 at 3:35 PM
10 5SkepticalSean, Dr.CardioMD, EndoResFellow and 7 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
lucas_SP_BR
Member
456
1,890
Jun 2024
São Paulo, BR
Jan 9, 2024 at 1:31 PM#4
NeuroNate said:
The list price and the price I actually pay differ by a factor of six depending on which of four routes I use, and none of that is transparent from…

Second this. Posting only so the count is not one.

9 4KarenAZ_mom, zoe_NC, Dr.ObesityLA and 6 others
Reply Quote Save Share Report
newstart_MO
New Member
12
45
Feb 2026
Springfield, MO
Jan 9, 2024 at 6:52 PM#5

Clinical perspective, offered as context rather than as advice.

Insurance update relevant to cost and coverage: I just got my prior auth approved through Blue Cross after 2 attempts.

What finally worked: a letter from my endocrinologist documenting BMI history (>3 years), failed diet attempts, comorbidities (T2DM + hypertension), and referencing the STEP trial data.

If your PA keeps getting denied, don't give up. Request a peer-to-peer review between your doctor and the insurance medical director. That's what finally broke through for me.

8 3RunnerRach, TrialNerd_Beth, HPLC_Greg and 5 others
Reply Quote Save Share Report

Similar Threads

STEP 1-5 trials comprehensive summary — efficacy endpoints compiled12 replies
Oral semaglutide 50mg Phase 3 — OASIS program results16 replies
Semaglutide pharmacokinetics — half-life, Tmax, steady state modeling10 replies
Compounded semaglutide stability data — temperature and light sensitivity16 replies
0.25mg → 2.4mg titration: optimal schedule based on clinical data6 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register